FARABEGOLI, FULVIA
FARABEGOLI, FULVIA
FABIT - DIPARTIMENTO DI FARMACIA E BIOTECNOLOGIE
FARABEGOLI F.; F .FARABEGOLI; FARABEGOLI FU
A RAD51/BRCA2 small molecule inhibitor enhances the antineoplastic effect of the PARPi talazoparib in pancreatic cancer
2023 Laura Poppi, Samuel H Myers, Viola Previtali, Francesco Rinaldi, Fulvia Farabegoli, Giuseppina Di Stefano, Naomi Walsh, Marinella Roberti, Andrea Cavalli
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer
2023 Myers, S. H.; Poppi, L.; Rinaldi, F.; Veronesi, M.; Ciamarone, A.; Previtali, V.; Bagnolini, G.; Schipani, F.; Ortega Martínez, J. A.; Girotto, S.; Di Stefano, G.; Farabegoli, F.; Walsh, N.; De Franco, F.; Roberti, M.; Cavalli, A.
Large Population Of Homogeneous Spheroids Models For Testing Toxicity And Diffusion Of Nanomaterials
2023 Emanuela Mensà, Ottavia Tartagni, Fulvia Farabegoli, Renato Brandimarti, Dario De Biase, Giampaolo Zuccheri
Proteomic profile of BxPC-3 cells after treatment with BRC4
2023 Viola Previtali, Samuel H. Myers, Laura Poppi, Kieran Wynne, Irene Casamassima Stefania Girotto, Giuseppina Di Stefano, Fulvia Farabegoli, Marinella Roberti, Giorgio Oliviero, Andrea Cavalli
Epigallocatechin-3-Gallate (EGCG) Mitigates Endothelial and Circulating Cells Alterations Following PLLA Electrospun Mat Placement
2022 Carmen Ciavarella, Ilenia Motta, Santino Blando, Sabrina Valente, Fulvia Farabegoli, Maria Letizia Focarete, Mauro Gargiulo, Gianandrea Pasquinelli
Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines
2022 Farabegoli F.; Granja A.; Magalhaes J.; Purgato S.; Voltattorni M.; Pinheiro M.
Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy
2022 Farabegoli, Fulvia; Pinheiro, Marina
Lactate is a potential promoter of tamoxifen resistance in MCF7 cells
2022 Rossi V.; Govoni M.; Farabegoli F.; Di Stefano G.
The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination
2022 Schipani, Fabrizio; Manerba, Marcella; Marotta, Roberto; Poppi, Laura; Gennari, Arianna; Rinaldi, Francesco; Armirotti, Andrea; Farabegoli, Fulvia; Roberti, Marinella; Di Stefano, Giuseppina; Rocchia, Walter; Girotto, Stefania; Tirelli, Nicola; Cavalli, Andrea
Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC)
2021 Petrocelli, Giovannamaria; Farabegoli, Fulvia; Valerii, Maria Chiara; Giovannini, Catia; Sardo, Alberto; Spisni, Enzo
EGCG mediated targeting of deregulated signaling pathways and non-coding rnas in different cancers: Focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways
2020 Farooqi A.A.; Pinheiro M.; Granja A.; Farabegoli F.; Reis S.; Attar R.; Sabitaliyevich U.Y.; Xu B.; Ahmad A.
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
2020 Bagnolini G.; Milano D.; Manerba M.; Schipani F.; Ortega J.A.; Gioia D.; Falchi F.; Balboni A.; Farabegoli F.; De Franco F.; Robertson J.; Pellicciari R.; Pallavicini I.; Peri S.; Minucci S.; Girotto S.; Di Stefano G.; Roberti M.; Cavalli A.
Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells
2019 Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Stefania Girotto, Roberto Pellicciari, and Andrea Cavalli
Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro
2018 Farabegoli, Fulvia*; Govoni, Marzia; Spisni, Enzo; Papi, Alessio
Betalains increase vitexin-2-O-xyloside cytotoxicity in CaCo-2 cancer cells
2017 Farabegoli, F.; Scarpa, E.S.; Frati, A.; Serafini, G.; Papi, A.; Spisni, E.; Antonini, E.; Benedetti, S.; Ninfali, P
EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion
2017 Farabegoli, Fulvia; Govoni, Marzia; Spisni, Enzo; Papi, Alessio
Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors
2017 Falchi, Federico; Giacomini, Elisa; Masini, Tiziana; Boutard, Nicolas; Di Ianni, Lorenza; Manerba, Marcella; Farabegoli, Fulvia; Rossini, Lara; Robertson, Janet; Minucci, Saverio; Pallavicini, Isabella; Di Stefano, Giuseppina; Roberti, Marinella; Pellicciari, Roberto; Cavalli, Andrea
Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines
2016 Papi, Alessio; Govoni, Marzia; Ciavarella, Carmen; Spisni, Enzo; Orlandi, Marina; Farabegoli, Fulvia
A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.
2014 Farabegoli F; Govoni M; Ciavarella C; Orlandi M; Papi A.
Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells
2013 A. Papi; F. Farabegoli; R. Iori; M. Orlandi; G.R. De Nicola; M. Bagatta ; D. Angelino; L. Gennari; P. Ninfali
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A RAD51/BRCA2 small molecule inhibitor enhances the antineoplastic effect of the PARPi talazoparib in pancreatic cancer | Laura Poppi, Samuel H Myers, Viola Previtali, Francesco Rinaldi, Fulvia Farabegoli, Giuseppina Di... Stefano, Naomi Walsh, Marinella Roberti, Andrea Cavalli | 2023-01-01 | - | FEBS PRESS | 4.03 Poster | - |
| An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer | Myers, S. H.; Poppi, L.; Rinaldi, F.; Veronesi, M.; Ciamarone, A.; Previtali, V.; Bagnolini, G.; ...Schipani, F.; Ortega Martínez, J. A.; Girotto, S.; Di Stefano, G.; Farabegoli, F.; Walsh, N.; De Franco, F.; Roberti, M.; Cavalli, A. | 2023-01-01 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | 1-s2.0-S0223523423010814-mmc1.docx; 1-s2.0-S0223523423010814-main.pdf |
| Large Population Of Homogeneous Spheroids Models For Testing Toxicity And Diffusion Of Nanomaterials | Emanuela Mensà, Ottavia Tartagni, Fulvia Farabegoli, Renato Brandimarti, Dario De Biase, Giampaol...o Zuccheri | 2023-01-01 | - | - | 4.02 Riassunto (Abstract) | - |
| Proteomic profile of BxPC-3 cells after treatment with BRC4 | Viola Previtali, Samuel H. Myers, Laura Poppi, Kieran Wynne, Irene Casamassima Stefania Girotto, ...Giuseppina Di Stefano, Fulvia Farabegoli, Marinella Roberti, Giorgio Oliviero, Andrea Cavalli | 2023-01-01 | JOURNAL OF PROTEOMICS | - | 1.01 Articolo in rivista | - |
| Epigallocatechin-3-Gallate (EGCG) Mitigates Endothelial and Circulating Cells Alterations Following PLLA Electrospun Mat Placement | Carmen Ciavarella, Ilenia Motta, Santino Blando, Sabrina Valente, Fulvia Farabegoli, Maria Letizi...a Focarete, Mauro Gargiulo, Gianandrea Pasquinelli | 2022-01-01 | BIOMEDICINES | - | 1.01 Articolo in rivista | biomedicines-10-01276-v2.pdf |
| Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines | Farabegoli F.; Granja A.; Magalhaes J.; Purgato S.; Voltattorni M.; Pinheiro M. | 2022-01-01 | ACS OMEGA | - | 1.01 Articolo in rivista | acsomega.2c01829(2022).pdf |
| Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy | Farabegoli, Fulvia; Pinheiro, Marina | 2022-01-01 | FRONTIERS IN PHARMACOLOGY | - | 1.01 Articolo in rivista | fphar-13-809706.pdf |
| Lactate is a potential promoter of tamoxifen resistance in MCF7 cells | Rossi V.; Govoni M.; Farabegoli F.; Di Stefano G. | 2022-01-01 | BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | - | 1.01 Articolo in rivista | Revised Manuscript.pdf |
| The Mechanistic Understanding of RAD51 Defibrillation: A Critical Step in BRCA2-Mediated DNA Repair by Homologous Recombination | Schipani, Fabrizio; Manerba, Marcella; Marotta, Roberto; Poppi, Laura; Gennari, Arianna; Rinaldi,... Francesco; Armirotti, Andrea; Farabegoli, Fulvia; Roberti, Marinella; Di Stefano, Giuseppina; Rocchia, Walter; Girotto, Stefania; Tirelli, Nicola; Cavalli, Andrea | 2022-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-23-08338-v3 (1).pdf |
| Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC) | Petrocelli, Giovannamaria; Farabegoli, Fulvia; Valerii, Maria Chiara; Giovannini, Catia; Sardo, A...lberto; Spisni, Enzo | 2021-01-01 | MOLECULES | - | 1.01 Articolo in rivista | molecules-26-00885.pdf |
| EGCG mediated targeting of deregulated signaling pathways and non-coding rnas in different cancers: Focus on JAK/STAT, Wnt/β-catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL mediated signaling pathways | Farooqi A.A.; Pinheiro M.; Granja A.; Farabegoli F.; Reis S.; Attar R.; Sabitaliyevich U.Y.; Xu B....; Ahmad A. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-12-00951.pdf |
| Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib | Bagnolini G.; Milano D.; Manerba M.; Schipani F.; Ortega J.A.; Gioia D.; Falchi F.; Balboni A.; F...arabegoli F.; De Franco F.; Robertson J.; Pellicciari R.; Pallavicini I.; Peri S.; Minucci S.; Girotto S.; Di Stefano G.; Roberti M.; Cavalli A. | 2020-01-01 | JOURNAL OF MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | ASAP_acs.jmedchem.9b01526.pdf |
| Rad51/Brca2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells | Marinella Roberti, Fabrizio Schipani, Greta Bagnolini, Domenico Milano, Elisa Giacomini, Federico... Falchi, Andrea Balboni, Marcella Manerba, Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Saverio Minucci, Isabella Pallavicini, Giuseppina Di Stefano, Stefania Girotto, Roberto Pellicciari, and Andrea Cavalli | 2019-01-01 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | - |
| Epigallocatechin-3-gallate and 6-OH-11-O-hydroxyphenanthrene limit BE(2)-C neuroblastoma cell growth and neurosphere formation in vitro | Farabegoli, Fulvia*; Govoni, Marzia; Spisni, Enzo; Papi, Alessio | 2018-01-01 | NUTRIENTS | - | 1.01 Articolo in rivista | nutrients-10-01141.pdf |
| Betalains increase vitexin-2-O-xyloside cytotoxicity in CaCo-2 cancer cells | Farabegoli, F.; Scarpa, E.S.; Frati, A.; Serafini, G.; Papi, A.; Spisni, E.; Antonini, E.; Benede...tti, S.; Ninfali, P | 2017-01-01 | FOOD CHEMISTRY | - | 1.01 Articolo in rivista | Farabegoli2017Copertina_GENERICA_UNIBO_postprint_IRIS-1.pdf |
| EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion | Farabegoli, Fulvia; Govoni, Marzia; Spisni, Enzo; Papi, Alessio | 2017-01-01 | BIOSCIENCE REPORTS | - | 1.01 Articolo in rivista | BSR20170168.full.pdf |
| Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors | Falchi, Federico; Giacomini, Elisa; Masini, Tiziana; Boutard, Nicolas; Di Ianni, Lorenza; Manerba..., Marcella; Farabegoli, Fulvia; Rossini, Lara; Robertson, Janet; Minucci, Saverio; Pallavicini, Isabella; Di Stefano, Giuseppina; Roberti, Marinella; Pellicciari, Roberto; Cavalli, Andrea | 2017-01-01 | ACS CHEMICAL BIOLOGY | - | 1.01 Articolo in rivista | - |
| Epigallocatechin-3-gallate Increases RXRγ-mediated Pro-apoptotic and Anti-invasive Effects in Gastrointestinal Cancer Cell Lines | Papi, Alessio; Govoni, Marzia; Ciavarella, Carmen; Spisni, Enzo; Orlandi, Marina; Farabegoli, Fulvia | 2016-01-01 | CURRENT CANCER DRUG TARGETS | - | 1.01 Articolo in rivista | - |
| A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines. | Farabegoli F; Govoni M; Ciavarella C; Orlandi M; Papi A. | 2014-01-01 | BIOMED RESEARCH INTERNATIONAL | - | 1.01 Articolo in rivista | BMRI2014.pdf; 853086.pdf |
| Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells | A. Papi; F. Farabegoli; R. Iori; M. Orlandi; G.R. De Nicola; M. Bagatta ; D. Angelino; L. Gennari...; P. Ninfali | 2013-01-01 | FOOD CHEMISTRY | - | 1.01 Articolo in rivista | - |